SEZI Share Price Performance
SEK 4.16
-0.54 (-11.40%)
67.5% undervalued intrinsic discount
SEK 12.80
Fair Value
Price SEK 4.16
AnalystConsensusTarget SEK 12.80
Fair ValueSEK 12.80
Share Pricen/a
Senzime AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
SEZI Community Narratives
AN
Fair Value SEK 12.8 67.5% undervalued intrinsic discount
US And European Guidelines Will Expand Neuromuscular Monitoring Adoption Worldwide
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US And European Guidelines Will Expand Neuromuscular Monitoring Adoption Worldwide
Key Takeaways Adoption driven by regulatory changes and expansion into new patient segments supports scalable, predictable growth and strengthens market position globally. Product innovation and recurring revenue streams improve margins, offsetting economic headwinds and enhancing long-term earnings stability.Read more
22
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
SEK 12.8
67.5% undervalued intrinsic discount
Fair Value
Profit Margin
8.2%
Future PE
73.4x
Price in 2028
SEK 8.41
Trending Discussion
Recently Updated Narratives
AN
US And European Guidelines Will Expand Neuromuscular Monitoring Adoption Worldwide
Fair Value: SEK 12.8 67.5% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Senzime AB (publ) Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 22, 2026
- -0.87
- 33.35%
- -132.11%
- 0%
About SEZI
- Founded
- 1999
- Employees
- 54
- CEO
- WebsiteView website
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue’s opposition to carrying an alternating electrical current. It also provides additional products, including CliniSenz Analyzer and OnZurf Probe. The company has a strategic connectivity and licensing agreement with Masimo to develop, manufacture, market, and distribute products that can connect to the Masimo Root patient monitoring system; license agreement with Fukuda Denshi Co. Ltd. to license TetraGraph technology; and license agreement with CoreSpiron (Henan) Co Ltd. to manufacture and sell ExSpiron system. Senzime AB (publ) was incorporated in 1999 and is headquartered in Uppsala, Sweden.
